

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/750,934	12/31/2003	Thomas E. Tarara	0101.00	1899	
21968 75 NEKTAR THER	90 03/21/2007 APEUTICS		EXAMINER		
150 INDUSTRIAL ROAD			SCHLIENTZ, LEAH H		
SAN CARLOS, CA 94070			ART UNIT	PAPER NUMBER	
			1618		
·	<u> </u>				
SHORTENED STATUTORY	PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
31 DAYS		03/21/2007	PAPER		

## Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Applic	ation No.	Applicant(s)				
Office Action Summary			),934	TARARA ET AL.				
			ner	Art Unit				
			chlientz	1618				
Period fo	The MAILING DATE of this communica or Reply	tion appears on	the cover sheet wi	th the correspondence ac	Idress			
WHIC - Exte after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE MAIL IN IT IS LONGER IN IT	LING DATE OF 17 CFR 1.136(a). In no cation. ory period will apply an by statute, cause the	THIS COMMUNIC event, however, may a red d will expire SIX (6) MON application to become AB	CATION.  eply be timely filed  THS from the mailing date of this of ANDONED (35 U.S.C. § 133).				
Status								
1)	Responsive to communication(s) filed of	nn .						
·			s non-final					
3)								
٠,۵	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	on of Claims							
4)⊠	Claim(s) 1-102 is/are pending in the ap	plication.						
•	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)□	5) Claim(s) is/are allowed.							
7)	Claim(s) is/are objected to.							
8)⊠	Claim(s) 1-102 are subject to restriction	n and/or election	requirement.					
Applicati	on Papers							
9)□	The specification is objected to by the E	xaminer.						
10)	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the				FR 1.121(d).			
11)	The oath or declaration is objected to by	the Examiner.	Note the attached	Office Action or form P	TO-152.			
Priority ι	ınder 35 U.S.C. § 119							
	12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.							
-/.								
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
•	application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.								
Attachmen	c(s)							
	e of References Cited (PTO-892)			ummary (PTO-413)				
	e of Draftsperson's Patent Drawing Review (PTO- nation Disclosure Statement(s) (PTO/SB/08)	948)		)/Mail Date formal Patent Application				
	No(s)/Mail Date		6) Other:					

Art Unit: 1618

#### **DETAILED ACTION**

#### Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-22 and 38-83, drawn to a pharmaceutical formulation for pulmonary administration, classified in class 514, subclass 31.
- II. Claims 23 37 and 84 102, drawn to a method of making a pharmaceutical formulation for pulmonary administration comprising suspending active agent particles in a hydrophobic material in a liquid feedstock and spray drying the feedstock suspension, classified in class 424, subclass 490.

**NOTE:** In addition to the elected Group above, if Group II is elected, applicant is requested to elect a specific hydrophobic material from the distinct group thereof as set forth in the claims (e.g. claims 29 - 31 or 87 - 89) to which the preliminary search for the elected Group will be limited. The different structures included therein are a diverse set and are independent and distinct structures, including phospholipids and amino acids, etc., which control the classification, thus, necessitate a specific election to which the elected Group will be drawn.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the

Art Unit: 1618

process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the pharmaceutical formulation for pulmonary administration could be prepared by another materially different method, such as by sonication, various coating methods, etc., for example.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions have acquired a separate status in the art in view of their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species related to the hydrophobic material in Group II: phospholipids and amino acid. The species are independent or distinct because of their distinct structural characteristics which control the classification.

Art Unit: 1618

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 23 - 28, 32 - 37, 84 - 86, and 90 - 94 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

A telephone call was not made to request an oral election to the above restriction requirement because of the complexity of the restriction / election of species regirement.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not

Art Unit: 1618

distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### Notice of Potential Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

Art Unit: 1618

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leah Schlientz whose telephone number is 571-272-9928. The examiner can normally be reached on Monday - Friday 8 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1618

Page 7

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

LHS

MICHAEL G. HARTLEY
SUPERVISORY PATENT EXAMINER